Get the Stockscreener App
5.95
2.76%
0.16
Candel Therapeutics Inc stock is traded at $5.95, with a volume of 677.51K.
It is up +2.76% in the last 24 hours and down -10.79% over the past month.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$5.79
Open:
$5.84
24h Volume:
677.51K
Relative Volume:
0.75
Market Cap:
$326.63M
Revenue:
$124.00K
Net Income/Loss:
$-49.99M
P/E Ratio:
-3.5207
EPS:
-1.69
Net Cash Flow:
$-31.03M
1W Performance:
-2.30%
1M Performance:
-10.79%
6M Performance:
-48.84%
1Y Performance:
+12.05%
1-Day Range:
$5.80
$6.175
1-Week Range:
$5.45
$6.175
52-Week Range:
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
5.95 | 298.61M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Resumed | H.C. Wainwright | Buy |
| Feb-20-25 | Initiated | Citigroup | Buy |
| Feb-19-25 | Initiated | Canaccord Genuity | Buy |
| Feb-07-25 | Initiated | BofA Securities | Buy |
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
View All
Candel Therapeutics Inc Stock (CADL) Latest News
Candel Therapeutics Insider Ups Holding By 22% During Year - simplywall.st
Candel Therapeutics Advances with Promising Cancer Therapies - TipRanks
Bullish Candlestick Pattern Forms in Candel Therapeutics Inc.Price Action & AI Driven Price Predictions - classian.co.kr
Candel Therapeutics Posts Q2 2025 Loss, But History Suggests Strong Post-Earnings Recovery Potential - AInvest
Candel Therapeutics Faces Uncertainty Despite FDA RMAT Designation for Prostate Cancer Treatment - MSN
Candel Therapeutics Posts Loss in Q2 2025; Surprising Market Resilience Sparks Investor Interest - AInvest
Candel Therapeutics secures RMAT for prostate cancer – ICYMI - Proactive financial news
Candel Therapeutics reports Q2 EPS (9c) vs. (74c) last year - MSN
Candel Therapeutics Inc. Matches Institutional Buying Filter2025 Market Outlook & Long-Term Investment Growth Plans - newsyoung.net
Candel Therapeutics: Promising Pipeline Developments and Strategic Advancements Support Buy Rating - TipRanks
Candel eyes 2026 U.S. filing for CAN-2409 after Phase 3 success and FDA RMAT status - Proactive financial news
Candel Therapeutics’ CAN-2409: Promising Phase 3 Results and Market Potential - TipRanks
Candel Therapeutics shares fall 5.16% intraday despite positive clinical trial results and regulatory designations. - AInvest
Candel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Small cap wrap: Lancaster Resources, Candel Therapeutics, atai Life Sciences, Charbone Hydrogen... - Proactive financial news
Candel Therapeutics sees cash runway into 1Q27 - TipRanks
CCORF Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛
Candel Therapeutics Advances Prostate Cancer Therapy Filing After Successful Trial - AInvest
Candel Therapeutics advances toward prostate cancer therapy filing after trial success - Proactive financial news
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Candel Therapeutics, Inc. SEC 10-Q Report - TradingView
Candel's Prostate Cancer Treatment Secures FDA Fast Track After Breakthrough Trial Results - Stock Titan
Can Candel Therapeutics Inc. be recession proofJuly 2025 Sentiment & Low Drawdown Investment Strategies - classian.co.kr
Can Candel Therapeutics Inc. grow without dilutionWeekly Gains Report & Long Hold Capital Preservation Plans - newsyoung.net
Candel Therapeutics Inc. Stages Intraday Comeback — Trend ChangeReal Trader Watchlist of Hot Stocks Released - beatles.ru
Candel Therapeutics CADL 2025Q2 Earnings Preview Downside Ahead on Lack of Revenue Data - AInvest
Cancer Vaccines Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon - The Globe and Mail
Candel Therapeutics Institutional Ownership Soars to 44%: Implications for Stock Price Sensitivity - AInvest
Candel Therapeutics shares fall 2.76% intraday after announcing clinical trial initiation for tecarfarin in dialysis patients. - AInvest
How strong is Candel Therapeutics Inc. company’s balance sheetAchieve explosive financial results today - Jammu Links News
What are the latest earnings results for Candel Therapeutics Inc.Achieve consistent double-digit growth - Jammu Links News
What are Candel Therapeutics Inc. company’s key revenue driversCapitalize on market trends early - Jammu Links News
Is it the right time to buy Candel Therapeutics Inc. stockMaximize profits with strategic stock selection - Jammu Links News
How many analysts rate Candel Therapeutics Inc. as a “Buy”Dynamic investment growth - Jammu Links News
What catalysts could drive Candel Therapeutics Inc. stock higher in 2025Phenomenal returns - Jammu Links News
Candel Therapeutics Inc. Stock Analysis and ForecastUnlock powerful portfolio management tools - Jammu Links News
Is Candel Therapeutics Inc. stock overvalued or undervaluedFree Technical Analysis Support - Jammu Links News
What makes Candel Therapeutics Inc. stock price move sharplyGain the edge with real-time market data - Jammu Links News
Is Candel Therapeutics Inc. a growth stock or a value stockFree Stock Data Feed Backed By Experts - jammulinksnews.com
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know - MSN
Applying Wyckoff theory to Candel Therapeutics Inc. stockTop Gaining Picks With Entry Signals Identified - metal.it
Candel Therapeutics CMO Garrett Buys, Sells Shares Amid Company's Market Performance. - AInvest
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Why Candel Therapeutics Inc. stock attracts strong analyst attentionMomentum Based Equity Trading Plans Reviewed - beatles.ru
Candel Therapeutics to share company update at Canaccord Genuity Growth Conference - Proactive financial news
Candel Therapeutics CEO Dr. Tak to Share Cancer Immunotherapy Progress at Major Growth Conference - Stock Titan
Is Candel Therapeutics Inc. Stock a Good Fit for Conservative InvestorsAI Driven Buy Alert Trade Blueprint Released - metal.it
Published on: 2025-07-29 16:45:46 - metal.it
What machine learning models say about Candel Therapeutics Inc.Swing Trading Entry Signals Suggest Opportunity Zone - metal.it
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Candel Therapeutics Inc Stock (CADL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nichols William Garrett | Chief Medical Officer |
Jul 28 '25 |
Sale |
6.98 |
937 |
6,540 |
52,493 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Option Exercise |
1.29 |
781 |
1,007 |
53,274 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Sale |
5.04 |
781 |
3,936 |
52,493 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):